Intelligent Bio Solutions Demonstrates Robust Growth with Increased Cartridge Sales and Narrowing Losses

Intelligent Bio Solutions (Nasdaq: INBS) has revealed substantial financial progress in its fiscal third quarter of 2025, highlighting strategic growth and operational improvements in the medical technology sector. The company reported a 20% sequential revenue increase to $728,867, primarily fueled by expanding cartridge sales that now represent 58% of total revenue.

The financial results demonstrate notable improvements across multiple metrics. Gross profit surged 91% year-over-year to $341,368, while the company successfully narrowed its net loss by $434,141 to $2.54 million. These figures suggest ongoing operational efficiency and strategic cost management.

A key component of the company's growth strategy involves customer base expansion. During the quarter, Intelligent Bio Solutions added 35 new accounts, bringing its total active customer base to over 450. The company has been actively pursuing international market penetration through strategic partnerships and system upgrades designed to support multilingual operations.

The company's technological innovation continues to drive its market positioning. By securing its sixth U.S. patent and advancing regulatory efforts across global markets, Intelligent Bio Solutions is strengthening its competitive stance in the rapidly evolving medical technology landscape.

The Intelligent Fingerprinting Drug Screening System remains a cornerstone of the company's offering, providing rapid, non-invasive testing capabilities across various industries. With sample collection taking mere seconds and results available in under ten minutes, the technology presents a potentially transformative solution for workplace drug screening in sectors including construction, manufacturing, transportation, and logistics.

As the medical technology sector continues to evolve, Intelligent Bio Solutions' focused approach on developing efficient, rapid testing technologies positions the company as a potential innovator in non-invasive diagnostic solutions. The company's ability to improve financial performance while expanding its technological capabilities suggests a promising trajectory for future growth and market penetration.